iBio to Initiate Phase 1 Trial of IBIO-600 in Australia Following Regulatory Clearance

On April 8, 2026, iBio, Inc. announced it received Clinical Trial Notification (CTN) acknowledgement from Australia’s Therapeutic Goods Administration (TGA) and ethics approval to initiate a Phase 1 clinical trial of IBIO-600. IBIO-600 is a long-acting anti-myostatin monoclonal antibody designed to preserve muscle mass and improve body composition, particularly in patients undergoing weight loss treatments like GLP-1 therapies. The Phase 1 study is a randomized, double-blind, placebo-controlled trial evaluating safety, tolerability, and pharmacokinetics in overweight and obese participants. The company expects to dose the first participant in the second quarter of 2026. Additionally, the public announcement triggered a 30-trading-day expiration countdown for the company's outstanding Series G Warrants. These warrants, which were issued in August 2025, are now set to expire on May 12, 2026. If all 27,945,000 outstanding Series G Warrants are exercised, the company will issue an equivalent number of common shares and Series H Warrants.